Skip to content

Study · Case report or series · n = 3 · 2026

4 results

"Ozempic Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation.

Bykowski J, Loewen G, Loewen B, Seslija D

American journal of physical medicine & rehabilitation26 Mar 2026

PMID41955540 (opens in a new tab)DOI10.1097/phm.0000000000002989 (opens in a new tab)PepBankPUB-41955540
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In 3 patients with prosthetic limbs who used semaglutide, skin breakdown was reported as a complication.

    In plain wordsIn 3 people with artificial limbs, skin breakdown was reported after they started semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseSkin breakdown
    Study

    n = 3

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Herein, we describe 3 cases of semaglutide use in patients with prosthetic limbs who subsequently presented with a variety of complications, including skin breakdown, disproportionate residual limb volume loss, decreased prosthetic use, and increased residual limb pain.
  2. 02HumanCase report or seriesSafety outcome

    In 3 patients with prosthetic limbs who used semaglutide, disproportionate residual limb volume loss was reported as a complication.

    In plain wordsIn 3 people with artificial limbs, the remaining limb lost disproportionate volume after they started semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseResidual limb volume loss
    Study

    n = 3

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Herein, we describe 3 cases of semaglutide use in patients with prosthetic limbs who subsequently presented with a variety of complications, including skin breakdown, disproportionate residual limb volume loss, decreased prosthetic use, and increased residual limb pain.
  3. 03HumanCase report or seriesOther

    In 3 patients with prosthetic limbs who used semaglutide, decreased prosthetic use was reported as a complication.

    In plain wordsIn 3 people with artificial limbs, use of the artificial limb fell after they started semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseProsthetic use
    Study

    n = 3

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Herein, we describe 3 cases of semaglutide use in patients with prosthetic limbs who subsequently presented with a variety of complications, including skin breakdown, disproportionate residual limb volume loss, decreased prosthetic use, and increased residual limb pain.
  4. 04HumanCase report or seriesSafety outcome

    In 3 patients with prosthetic limbs who used semaglutide, increased residual limb pain was reported as a complication.

    In plain wordsIn 3 people with artificial limbs, pain in the remaining limb increased after they started semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseResidual limb pain
    Study

    n = 3

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Herein, we describe 3 cases of semaglutide use in patients with prosthetic limbs who subsequently presented with a variety of complications, including skin breakdown, disproportionate residual limb volume loss, decreased prosthetic use, and increased residual limb pain.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.